Mark Corrigan
CIK 1250661 · President & CEO · last filed 2026-10-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SEPR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CAMBRIDGE, MA 02138-1002
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WVE | Director | 39,515 | $3.25 | $128.6K | -$217.3K | 9 | 2026-10-07 |
| TREVENA INC (TRVN) Delisted | Director | — | $0.01 | — | $0 | 2 | 2024-06-14 |
| Nabriva Therapeutics plc (NBRV) Delisted | Director | 288 | $1.42 | $409 | -$2.0K | 6 | 2022-08-04 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | — | — | — | $0 | 3 | 2018-08-13 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | Director | — | — | — | $0 | 3 | 2017-03-01 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Director | 21,859 | — | — | $0 | 2 | 2015-06-08 |
| CUBIST PHARMACEUTICALS INC (CBST.Z) Delisted | Director | 0 | — | — | -$400.0K | 2 | 2015-01-21 |
| CUBIST PHARMACEUTICALS INC (CBST) Delisted | Director | 5,498 | — | — | -$1.17M | 9 | 2013-06-14 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | President & CEO | 87,205 | — | — | $0 | 3 | 2010-03-03 |
| SEPRACOR INC /DE/ (SEPR) Delisted | Executive VP, R&D | 70,668 | — | — | -$7.62M | 10 | 2009-10-19 |
Recent Filings · Page 6 of 7
61 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-06-08 | CUBIST PHARMACEUTICALS INC (CBST) Delisted | Grant (A) | +658 | $12.0K | EDGAR |
| 2009-05-14 | SEPRACOR INC /DE/ (SEPR) Delisted | Grant (A) | +35,000 | $504.0K | EDGAR |
| 2009-05-05 | SEPRACOR INC /DE/ (SEPR) Delisted | Sell (S) | −5,483 | -$75.2K | EDGAR |
| 2008-06-24 | CUBIST PHARMACEUTICALS INC (CBST) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-06-05 | SEPRACOR INC /DE/ (SEPR) Delisted | Sell (S) | −5,500 | -$115.1K | EDGAR |
| 2008-05-22 | SEPRACOR INC /DE/ (SEPR) Delisted | Grant (A) | +35,000 | $744.1K | EDGAR |
| 2007-06-15 | SEPRACOR INC /DE/ (SEPR) Delisted | Mixed | +142,778 | $1.71M | EDGAR |
| 2007-06-15 | SEPRACOR INC /DE/ (SEPR) Delisted | Sell (S) | −12,010 | -$568.5K | EDGAR |
| 2007-06-15 | SEPRACOR INC /DE/ (SEPR) Delisted | Sell (S) | −103,232 | -$4.86M | EDGAR |
| 2007-05-17 | SEPRACOR INC /DE/ (SEPR) Delisted | Grant (A) | +17,500 | $933.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.